Precision Oncology’s Next Investment Is the Pathway Between the Report and Treatment

01 / THE ARGUMENT

The investment decision begins after sequencing

Precision oncology is often purchased as an information product: a larger panel, a faster laboratory, a richer report. Its business value, however, depends on whether information changes a feasible care decision. My thesis is that a cancer service with adequate testing capacity should prioritize the pathway from report to action. That is a debatable allocation choice. A hospital with major testing gaps may need more testing first; a hospital already generating unused results probably needs something else.

The relevant unit of production is a completed, clinically justified decision. That includes selecting a supported therapy, identifying an appropriate trial, documenting why a finding is not actionable, or deciding that another course better reflects the patient’s condition and preferences. Counting tests or molecular recommendations rewards intermediate activity. Counting documented decisions places responsibility on the whole service line.

02 / THE ARGUMENT

Three studies describe different parts of the problem

The ROME phase 2 trial randomized 400 selected patients with advanced solid tumors after screening 1,794. Genomically tailored treatment improved objective response, 17.5% versus 10%, and progression-free survival, with a hazard ratio of 0.66; median overall survival was similar. The open-label trial included substantial crossover and patients who reached molecular review and randomization. It supports a treatment strategy in that population, not a survival promise for everyone offered profiling. [1]

In the Belgian BALLETT implementation study, 872 patients from 12 hospitals entered a decentralized profiling program. The investigators reported actionable markers in 81%, treatment recommendations in 69%, and matched treatment in 23%. Those are different stages of a pathway, not interchangeable definitions of success. This nonrandomized study establishes feasibility and exposes attrition; it cannot assign the entire gap to avoidable operational failure. [2]

A September 2026 retrospective study from one Japanese university hospital examined 882 profiling episodes. Median laboratory turnaround was 14 days among 871 evaluable episodes; median consent-to-patient-disclosure time was 41 days among 828. The endpoints and denominators differ, so subtracting the medians would not establish each patient’s post-laboratory delay. The finding nevertheless shows why a laboratory service-level agreement is an incomplete measure of patient-facing timeliness. [3]

03 / THE ARGUMENT

Separate biological potential from operational inference

A molecular alteration can create a treatment possibility without creating an immediately usable option. The service must connect specimen adequacy, interpretation, clinical eligibility, available treatment, funding and a patient’s decision. Each stage has a different owner. My inference from the evidence is that managers should examine those handoffs before concluding that broader testing alone will improve delivery. None of these studies directly randomizes a navigation operating model against purchasing additional assay capacity.

That distinction prevents a harmful incentive: maximizing the proportion receiving matched treatment irrespective of clinical appropriateness. A responsible dashboard should distinguish biological nonactionability, deterioration, unavailable trials, treatment access barriers, declined treatment and administrative delay. The organization can then invest in the losses it can influence. It should also record informed decisions against treatment as successful completion of the process, while separately evaluating clinical outcomes.

04 / THE ARGUMENT

Price the counterfactual, not the number of reports

Let N be the eligible annual population, q the proportion reaching a timely, clinically justified decision, and Δq the improvement expected from redesign. Let V be the locally assessed value per additional completed decision, including supported quality benefits and any legitimate financial contribution. An illustrative planning equation is net program value = N × Δq × V + avoided rework − navigation cost − interpretation cost − incremental downstream cost. This is a decision framework, not an effect estimate from the studies.

The counterfactual must specify what would otherwise happen. A faster discussion may replace an unnecessary repeat consultation, or merely move an already scheduled consultation earlier. A matched treatment may add drug spending while delivering worthwhile benefit. A trial referral may require substantial travel support without generating local revenue. The finance team should therefore present provider cash flow, payer spending and patient value separately, and avoid selling a clinical improvement as guaranteed cost reduction.

05 / THE ARGUMENT

Give one owner authority across the handoffs

Consider a regional cancer network choosing between another broad-panel contract and a six-month precision-care pathway pilot. The oncology service-line director should own the pilot, with the molecular pathology lead responsible for specimen and report quality, and a designated navigator responsible for visible next actions. The pilot should begin in a defined advanced-cancer cohort selected by clinical leadership. The operational boundary is essential: the project evaluates delivery around appropriate testing, not a blanket expansion of testing indications.

At ordering, the navigator records the intended decision date and access needs. When results arrive, a shared queue assigns interpretation and patient discussion. A designated clinician records the decision, evidence level and unresolved access barriers. Pharmacy and trial teams begin feasibility checks early enough to inform discussion. The initial budget pays for protected coordination time, interpretation capacity and essential access support; expensive laboratory expansion waits until the pilot identifies a capacity constraint it can actually solve.

06 / THE ARGUMENT

Specify how this thesis could be wrong

The pathway hypothesis fails if baseline measurement shows that laboratory scarcity dominates delays, most patients already receive timely decisions, or additional coordination creates appointments without changing care. It also fails economically when the plausible benefit of closing remediable gaps is smaller than the full operating cost. Leaders should compare the pilot with a contemporaneous service or use a staged rollout where feasible, accounting for disease mix, clinical urgency and changes in available treatments.

Risks include overinterpretation of weak molecular evidence, excessive referrals, tissue depletion, privacy failures and unequal access to navigation. Timeliness metrics can also be gamed through superficial disclosures. Audit a sample of completed cases for decision quality and patient understanding. Track unresolved cases from the original eligible denominator, stratify access measures by relevant population characteristics, and review patient burden. A faster administrative endpoint is not sufficient evidence of better care.

07 / THE ARGUMENT

Allocate capital to the measured bottleneck

The executive decision is conditional but concrete: fund an accountable pathway, then earn the right to expand testing with evidence of unmet demand. Set an upfront expenditure ceiling and require a review after the first operating quarter. The review should show where patients leave the pathway, how quickly clinically useful discussions occur, and what proportion of remediable failures the team resolves. Clinical governance should retain authority over treatment appropriateness.

If the service discovers a genuine assay bottleneck, laboratory capacity becomes the rational next purchase. If the bottleneck is access to treatment, another sequencing instrument will not remove it. Precision oncology can justify substantial investment, but its investment case should be written around the decision that reaches the patient. The scientific opportunity and the operating system must be financed together.